In this episode of ToxChats, Dr. Daniel Rudmann, an ACVP board-certified investigative and toxicologic pathologist and translational medicine scientist with over 20 years of experience in drug discovery and development and current director of digital pathology at Charles River Laboratories, is interviewed. Dr. Rudmann discusses how advances in digital pathology and machine learning are improving toxicology pathology workflows.

For further information on digital pathology in drug discovery, we encourage you to check out the following links:
1. Society of Toxicologic Pathology Digital Pathology and Image Analysis Special Interest Group Article*: Opinion on the Application of Artificial Intelligence and Machine Learning to Digital Toxicologic Pathology
https://journals.sagepub.com/doi/10.1177/0192623319881401?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

2. BIGPICTURE is a public-private partnership funded by the EU Innovative Medicines Initiative (IMI) bringing together academic institutions, small- and medium-sized enterprises, public organizations, pharmaceutical companies, and a large network of partners.
https://bigpicture.eu/